计算方法:基于原子的3D-QSAR,分子对接,ADME-Tox,MD模拟和DFT,以找到新的多目标抗结核剂
Debadash Panigrahi1,2, Susanta Kumar Sahu3
1University Department of Pharmaceutical Sciences, Utkal University, VaniVihar, Bhubaneswar, Odisha, 751004, India. debmpharm@yahoo.co.in.
BMC chemistry
|February 13, 2025
概括
耐药结核病 (TB) 需要新的治疗方法. 计算方法确定了MK3,这是一个有前途的多向抗结核剂,表现出稳定性和对关键结核蛋白的高结合亲和力.
科学领域:
- 计算化学和药物发现
- 药品化学和药理学 药品化学和药理学
- 分子建模和模拟分子模型
背景情况:
- 结核病 (TB) 构成了严重的全球健康威胁,原因是 Mycobacterium tuberculosis (MTB) 的耐药性增加.
- 现有的抗结核药物对抗性菌株的效果越来越差,需要开发新的治疗策略.
- 计算工具为设计新的多向抗结核剂提供了一个有希望的途径,以对抗耐药的MTB.
研究的目的:
- 使用计算方法设计新的多向抗结核剂,以克服Mycobacterium结核病的耐药性.
- 为了识别具有高结合亲和度的强效化合物,对抗关键的结核病点蛋白质,埃诺酸载体蛋白还原酶 (InhA) 和Decaprenyl酸-β-D-Ribose20-epimerase (DprE1).
- 通过分子动力学模拟来评估化合物的分子稳定性和结合特性.
主要方法:
- 结合3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,3D-QSAR,4D-QSAR,5D-QSAR,5D-QSAR,5D-QSAR,5D-QSAR,5D-QSAR,5D-QSAR,5D-QSAR,5D-QSAR,5D-QSAR,5D-QSAR,5D-QSAR,5D-QSAR,5
- 从PubChem数据库中对237种化合物的虚拟选使用与经过验证的药理模型相比的相似性搜索进行.
- 进行了分子对接,分子动力学模拟 (100 ns使用GROMACS),并分析了分子轨道属性 (HOMO,LUMO,能量差距).
主要成果:
- 开发了一个具有统计意义的3D-QSAR模型,R2 = 0.9521和Q2 = 0.8589,表明高预测准确度.
- 化合物MK3对InhA (PDBID: 2NSD) 和DprE1 (PDBID: 4FDO) 均表现出很好的对接得分 (-9.2和-8.3kJ/mol).
- 分子动力学模拟证实了MK3在InhA和DprE1.1活性位点内的热力学稳定性和有效结合.
结论:
- 已识别的化合物MK3显示出作为一种新型多向抗结核剂的巨大潜力.
- MK3具有很高的结合亲和力和有利的ADME-T特性,这表明它适合进一步的药物开发.
- 本研究所采用的计算策略对于设计新的抗结核病药物来对抗耐药菌株是有效的.
更多相关视频
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
7.8K
09:57Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
Published on: December 14, 2016
10.4K
相关概念视频
Structure-Activity Relationships and Drug Design
488
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
488
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Pulmonary Tuberculosis V
168
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
168
